126 related articles for article (PubMed ID: 21495413)
1. [Thrombohaemorrhagic syndrome in patients with a myeloproliferative disease with thrombocythemia].
Penka M; Kissová J; Buliková A; Zavrelová J; Ovesná J; Pavlík T
Vnitr Lek; 2011 Mar; 57(3):306-11. PubMed ID: 21495413
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
3. Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications.
Zucker S; Mielke CH
J Lab Clin Med; 1972 Sep; 80(3):385-94. PubMed ID: 5055386
[No Abstract] [Full Text] [Related]
4. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
5. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
6. [Platelet function in chronic myeloproliferative syndromes associated with thrombocytosis].
Grebe G; Pereira J; Mezzano D; Legues ME; Aranda E; Lira P
Rev Med Chil; 1985 Jan; 113(1):32-7. PubMed ID: 4081383
[No Abstract] [Full Text] [Related]
7. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
De Stefano V; Teofili L; Leone G; Michiels JJ
Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytosis and thrombocythemia.
Mitus AJ; Schafer AI
Hematol Oncol Clin North Am; 1990 Feb; 4(1):157-78. PubMed ID: 2155903
[TBL] [Abstract][Full Text] [Related]
9. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis.
Walsh PN; Murphy S; Barry WE
Thromb Haemost; 1977 Dec; 38(4):1085-96. PubMed ID: 579686
[TBL] [Abstract][Full Text] [Related]
10. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloproliferative diseases with an elevated platelet count (in excess of 1,000,000/microliter): a clinicopathological study on 46 patients with special emphasis on primary (essential) thrombocythemia.
Thiele J; Moedder B; Kremer B; Zankovich R; Fischer R
Hematol Pathol; 1987; 1(4):227-37. PubMed ID: 3504437
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
13. [What vascular events suggest a myeloproliferative disorder?].
Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
15. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution.
Sánchez-Luceros A; Meschengieser SS; Woods AI; Blanco AN; Kempfer AC; Casais P; Salviú MJ; Lazzari MA
Haematologica; 2002 Mar; 87(3):264-70. PubMed ID: 11869938
[TBL] [Abstract][Full Text] [Related]
16. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
17. Aspirin in essential thrombocythemia: status quo and quo vadis.
Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
[TBL] [Abstract][Full Text] [Related]
18. [Thrombocythemia with vascular thromboses in a young infant].
Majdalany E; Vassoyan J; Akatchérian C; Kyriakos S
J Med Liban; 1971; 24(3):295-9. PubMed ID: 5151411
[No Abstract] [Full Text] [Related]
19. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
20. [Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
Sidorova LD; Arkhipov BF; Degtiareva MM; Barkagan LZ
Ter Arkh; 1981; 53(9):91-5. PubMed ID: 7302866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
